Therapy to improve wellbeing in young brain tumor survivors
Acceptance and Commitment Therapy for Young Brain Tumour Survivors: An Acceptability and Feasibility Trial
This study is testing whether a new online therapy can help young brain tumor survivors aged 11-24 feel better and improve their quality of life after treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 72 (estimated) |
| Ages | 11 Years to 24 Years |
| Sex | All |
| Sponsor | Nottingham University Hospitals NHS Trust Academic / other |
| Locations | 1 site (Nottingham) |
| Trial ID | NCT04722237 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility and acceptability of remotely delivered Acceptance and Commitment Therapy (ACT) for improving the quality of life in young survivors of brain tumors aged 11-24 years. Participants will be randomly assigned to receive 12 weeks of ACT immediately or after a 12-week wait, with follow-up assessments conducted at 24, 36, and 48 weeks to measure the durability of treatment effects. The study aims to address the significant physical and psychological challenges faced by this population after completing cancer treatment.
Who should consider this trial
Good fit: Ideal candidates are young individuals aged 11-24 who have completed treatment for a brain tumor and have stable health for at least six months.
Not a fit: Patients currently undergoing treatment for brain tumors or those with severe psychological conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this therapy could significantly enhance the quality of life for young brain tumor survivors.
How similar studies have performed: Other studies have shown promise in using psychological interventions like ACT for improving quality of life in cancer survivors, suggesting a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 11-to-24 years at the time of randomisation * Received treatment for a brain tumour at a participating Principle Treatment Centre * Active brain tumour treatment is complete and their condition stable for at least six-months * Have sufficient cognitive ability to engage with ACT sessions as judged by the clinician at baseline assessment * competent to provide informed consent (participants aged 16 or over) or assent (participants aged 11-15) * Parent/carer competent to provide informed consent (for participants aged 11-15) Exclusion Criteria: * Received a structured behavioural intervention within six-months prior to study recruitment * Previous or current alcohol/substance dependence, psychosis, suicidality, or eating disorder * Moderate or severe intellectual disability, confirmed through researcher judgement at screening through questions relating to school type and previous diagnoses * Immediate risk to self or others * The patient or their parent/carer is not able to speak, read or write English
Where this trial is running
Nottingham
- Sophie Thomas — Nottingham, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Sophie Thomas, DClinPsy — Nottingham University Hospitals NHS Trust
- Study coordinator: Sophie Thomas, DClinPsy
- Email: Sophie.Thomas@nhs.net
- Phone: 0115 9249924
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.